170 related articles for article (PubMed ID: 32802094)
1. Proteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-cell Acute Lymphoblastic Leukemia Cell Line.
Hosseini MS; Mohammadi MH; Vahabpour Roudsari R; Jafari L; Mashati P; Gharehbaghian A
Iran J Pharm Res; 2019; 18(Suppl1):132-145. PubMed ID: 32802094
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of Carfilzomib for Infant
Cheung LC; de Kraa R; Oommen J; Chua GA; Singh S; Hughes AM; Ferrari E; Ford J; Chiu SK; Stam RW; Kees UR; Malinge S; Kotecha RS
Front Oncol; 2021; 11():631594. PubMed ID: 33937032
[TBL] [Abstract][Full Text] [Related]
3. Pyr3, a TRPC3 channel blocker, potentiates dexamethasone sensitivity and apoptosis in acute lymphoblastic leukemia cells by disturbing Ca(2+) signaling, mitochondrial membrane potential changes and reactive oxygen species production.
Abdoul-Azize S; Buquet C; Vannier JP; Dubus I
Eur J Pharmacol; 2016 Aug; 784():90-8. PubMed ID: 27179991
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.
Gao M; Chen G; Wang H; Xie B; Hu L; Kong Y; Yang G; Tao Y; Han Y; Wu X; Zhang Y; Dai B; Shi J
Oncotarget; 2016 May; 7(20):29102-15. PubMed ID: 27074555
[TBL] [Abstract][Full Text] [Related]
5. [Effects of decitabine against acute T lymphoblastic leukemia cell line Molt4].
Liu J; Huang C; Cheng H; Tang G; Hu X; Zhou H; Wang J; Yang J
Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):230-4. PubMed ID: 25854468
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
7. [P38 mitogen-activated protein kinase mediates glucocorticoid receptor function induced by dexamethasone in acute lymphoblastic leukemia cells].
He L; Li D; Hou KZ; Liu YP
Zhonghua Er Ke Za Zhi; 2007 Sep; 45(9):687-91. PubMed ID: 18021564
[TBL] [Abstract][Full Text] [Related]
8. Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305.
Augustin E; Moś-Rompa A; Skwarska A; Witkowski JM; Konopa J
Biochem Pharmacol; 2006 Dec; 72(12):1668-79. PubMed ID: 16970926
[TBL] [Abstract][Full Text] [Related]
9. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
10. Low-dose anisomycin sensitizes glucocorticoid-resistant T-acute lymphoblastic leukemia CEM-C1 cells to dexamethasone-induced apoptosis through activation of glucocorticoid receptor and p38-MAPK/JNK.
Liu Y; Ge J; Li Q; Guo X; Gu L; Ma ZG; Li XH; Zhu YP
Leuk Lymphoma; 2014 Sep; 55(9):2179-88. PubMed ID: 24597985
[TBL] [Abstract][Full Text] [Related]
11. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
12. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.
Bonapace L; Bornhauser BC; Schmitz M; Cario G; Ziegler U; Niggli FK; Schäfer BW; Schrappe M; Stanulla M; Bourquin JP
J Clin Invest; 2010 Apr; 120(4):1310-23. PubMed ID: 20200450
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.
Guo X; Zhou CY; Li Q; Gao J; Zhu YP; Gu L; Ma ZG
Biomed Environ Sci; 2013 May; 26(5):371-81. PubMed ID: 23611130
[TBL] [Abstract][Full Text] [Related]
15. MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy.
Polak A; Kiliszek P; Sewastianik T; Szydłowski M; Jabłońska E; Białopiotrowicz E; Górniak P; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Nowis D; Gołąb J; Giebel S; Lech-Marańda E; Warzocha K; Juszczyński P
PLoS One; 2016; 11(5):e0155893. PubMed ID: 27196001
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.
Liu CY; Hsieh FS; Chu PY; Tsai WC; Huang CT; Yu YB; Huang TT; Ko PS; Hung MH; Wang WL; Shiau CW; Chen KF
Br J Haematol; 2017 Jun; 177(5):726-740. PubMed ID: 28340282
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
Awan FT; Flynn JM; Jones JA; Andritsos LA; Maddocks KJ; Sass EJ; Lucas MS; Chase W; Waymer S; Ling Y; Jiang Y; Phelps MA; Byrd JC; Lucas DM; Woyach JA
Leuk Lymphoma; 2015; 56(10):2834-40. PubMed ID: 25669927
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21
Zhou Y; Wang K; Zhen S; Wang R; Luo W
Taiwan J Obstet Gynecol; 2016 Dec; 55(6):847-851. PubMed ID: 28040131
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.
Gao M; Gao L; Tao Y; Hou J; Yang G; Wu X; Xu H; Tompkins VS; Han Y; Wu H; Zhan F; Shi J
Acta Biochim Biophys Sin (Shanghai); 2014 Jun; 46(6):484-91. PubMed ID: 24801128
[TBL] [Abstract][Full Text] [Related]
20. KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.
Riz I; Hawley TS; Hawley RG
Oncotarget; 2015 Jun; 6(17):14814-31. PubMed ID: 26109433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
